Protection with antibody to tumor necrosis factor differs with similarly lethal Escherichia coli versus Staphylococcus aureus pneumonia in rats

Anesthesiology

Volumn 99, Issue 1, 2003, Pages 81-89

  Karzai, Waheedullah ^a,e   Cui, Xizhong ^d   Mehlhorn, Bjoern ^a   Straube, Eberhard ^b   Hartung, Thomas ^c   Gerstenberger, Eric ^d   Banks, Steven M ^d   Natanson, Charles ^d   Reinhart, Konrad ^a   Eichacker, Peter Q ^d  

^a Department of Anesthesiology ^*  (Germany)

^b University Hospital   (Germany)

^c UNIVERSITY OF KONSTANZ   (Germany)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e ZENTRALKLINIK BAD BERKA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOTIAM; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL PNEUMONIA; CONTROLLED STUDY; ESCHERICHIA COLI; HOST RESISTANCE; IMMUNOPROPHYLAXIS; LETHALITY; LUNG LAVAGE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STAPHYLOCOCCUS AUREUS; SURVIVAL RATE;

EID: 10744220246     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-200307000-00016     Document Type: Article

References (62)

1. Natanson C, Hoffman WD, Suffredini AF, Eichacker PQ, Danner RL: Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 1994; 120:771-83
2. Beutler B, Milsark IW, Cerami AC: Passive immunization against cachectin/ tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985; 229:869-71
3. Suitters AJ, Foulkes R, Opal SM, Palardy JE, Emtage JS, Rolfe M, Stephens S, Morgan A, Holt AR, Chaplin LC, Shaw NE, Nesbitt AM, Bodmer MW: Differential effect of isotype on efficacy of anti-tumor necrosis factor alpha chimeric antibodies in experimental septic shock. J Exp Med 1994; 179:849-56
4. Bagby GJ, Plessala KJ, Wilson LA, Thompson JJ, Nelson S: Divergent efficacy of antibody to tumor necrosis factor-alpha in intravascular and peritonitis models of sepsis. J Infect Dis 1991; 163:83-8
5. Mathison JC, Wolfson E, Ulevitch RJ: Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits. J Clin Invest 1988; 81:1925-37
6. Fiedler VB, Loof I, Sander E, Voehringer V, Galanos C, Fournel MA: Monoclonal antibody to tumor necrosis factor-alpha prevents lethal endotoxin sepsis in adult rhesus monkeys. J Lib Clin Med 1992; 120:574-88
7. Opal SM, Cross AS, Sadoff JC, Collins HH, Kelly NM, Victor GH, Palardy JE, Bodmer MW: Efficacy of antilipopolysaccharide and anti-tumor necrosis factor monoclonal antibodies in a neutropenic rat model of Pseudomonas sepsis. J Clin Invest 1991; 88:885-90
8. Stack AM, Saladino RA, Thompson C, Sattler F, Weiner DL, Parsonnet J, Nariuchi H, Siber GR, Fleisher GR: Failure of prophylactic and therapeutic use of a murine anti-tumor necrosis factor monoclonal antibody in Escherichia coli sepsis in the rabbit. Crit Care Med 1995; 23:1512-8
9. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A: Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330:662-4
10. Cross AS, Opal SM, Palardy JE, Bodmer MW, Sadoff JC: The efficacy of combination immunotherapy in experimental Pseudomonas sepsis. J Infect Dis 1993; 167:112-8
11. Opal SM, Cross AS, Kelly NM, Sadoff JC, Bodmer MW, Palardy JE, Victor GH: Efficacy of a monoclonal antibody directed against tumor necrosis factor in protecting neutropenic rats from lethal infection with Pseudomonas aeruginosa. J Infect Dis 1990; 161:1148-52
12. Hinshaw LB, Emerson TE Jr, Taylor FB Jr, Chang AC, Duerr M, Peer GT, Flournoy DJ, White GL, Kosanke SD, Murray CK, Xu R, Passey RB, Fournel MA: Lethal Staphylococcus aureus-induced shock in primates: Prevention of death with anti-TNF antibody, J Trauma 1992; 33:568-73
13. Hinshaw LB, Tekamp-Olson P, Chang AC, Lee PA, Taylor FB Jr, Murray CK, Peer GT, Emerson TE Jr, Passey RB, Kuo GC: Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha). Circ Shock 1990; 30:279-92
14. Jesmok G, Lindsey C, Duerr M, Foumel M, Emerson T Jr: Efficacy of monoclonal antibody against human recombinant tumor necrosis factor in E. coli-challenged swine. Am J Pathol 1992; 141:1197-207
15. Silva AT, Bayston KF, Cohen J: Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor-alpha in experimental gram-negative shock. J Infect Dis 1990; 162:421-7
16. Eskandari MK, Bolgos G, Miller C, Nguyen DT, DeForge LE, Remick DG: Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J Immunol 1992; 148:2724-30
17. Jin H, Yang R, Marsters SA, Bunting SA, Wurm FM, Chamow SM, Ashkenazi A: Protection against rat endotoxic shock by p55 tumor necrosis factor (TNF) receptor immunoadhesin: Comparison with anti-TNF monoclonal antibody. J Infect Dis 1994; 170:1323-6
18. Echtenacher B, Falk W, Mannel DN, Krammer PH: Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol 1990; 145:3762-6
19. Mastroeni P, Arena A, Costa GB, Liberto MC, Bonina L, Hormaeche CE: Serum TNF alpha in mouse typhoid and enhancement of a Salmonella infection by anti-TNF alpha antibodies. Microb Pathog 1991; 11:33-8
20. Ashkenazi A, Marsters SA, Capon DJ, Chamow SM, Figari IS, Pennica D, Goeddel DV, Palladino MA, Smith DH: Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. Proc Natl Acad Sci U S A 1991; 88:10535-9
21. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF: Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci U S A 1992; 89:4845-9
22. Russell DA, Tucker KK, Chinookoswong N, Thompson RC, Kohno T: Combined inhibition of interleukin-1 and tumor necrosis factor in rodent endotoxemia: Improved survival and organ function. J Infect Dis 1995; 171:1528-38
23. Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, Madani H, Widmer MB: Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993; 151:1548-61
24. Evans TJ, Moyes D, Carpenter A, Martin R, Loetscher H, Lesslauer W, Cohen J: Protective effect of 55- hut not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis. J Exp Med 1994; 180:2173-9
25. Kay CA: Cambridge Health Institute's Designing Better Drugs and Clinical Trials for Sepsis/SIRS: Reducing Mortality to Patients and Suppliers. Washington, DC, February 20, 1996
26. Dhainaut JF, Vincent JL, Richard C, Lejeune P, Martin C, Fierobe L, Stephens S, Ney UM, Sopwith M: CDP571, a humanized antibody to human tumor necrosis factor-alpha: Safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group. Crit Care Med 1995; 23:1461-9
27. Fisher CJ Jr, Opal SM, Dhainaut JF, Stephens S, Zimmerman JL, Nightingale P, Harris SJ, Schein RM, Panacek EA, Vincent JL, Foulke GE, Warren EL, Garrard C, Park G, Bodmer MW, Cohen J, Vanderlinden C, Cross AS, Sadoff JC, Fisher CJ, Panacek EA, Warren EL, Gorecki J, Opal SM, Dubin HG, Garner C, Kaye W, Dhainaut JF, Lanore JJ, Mira JP, Stephens S, Harris SJ, Bodmer MW, Zimmerman J, Dellinger RP, Taylor RW, Dahl S, Nightingale P, Shelly M., Mortimer A, Edwards JD, Schein RMH, Kett DH, Quartin A, Pena MA, Vincent JL, Bakker J, Foulke GE, Alberson TE, Walby W, Radcliffe J, Garrard C, Young D, McQuillam P, Park G, Cohen J, Bellingham G, Vanderlinden C, Burman W, Cross AS, Sadoff JS, Young L: Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group. Crit Care Med 1993; 21:318-27
28. Reinhart K, Wiegand-Lohnert C, Grimminger F, Kaul M, Withington S, Treacher D, Eckart J, Willatts S, Bouza C, Krausch D, Stockenhuber F, Eiselstein J, Daum L, Kempeni J: Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 1996; 24:733-42
29. Cohen J, Carlet J: INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 1996; 24:1431-40
30. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R, Pennington JE, Wherry JC: Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome: A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 1995; 273:934-41
31. Clark MA, Plank LD, Connolly AB, Streat SJ, Hill AA, Gupta R, Monk DN, Shenkin A, Hill GL: Effect of a chimeric antibody to tumor necrosis factor-alpha on cytokine and physiologic responses in patients with severe sepsis: A randomized, clinical trial. Crit Care Med 1998; 26:1650-9
32. Zeni F, Freeman B, Natanson C: Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment. Crit Care Med 1997; 25:1095-100
33. Abraham E, Anzueto A, Gutierrez G, Tessler S, San Pedro G, Wunderink R, Dal Nogare A, Nasraway S, Berman S, Cooney R, Levy H, Baughman R, Rumbak M, Light RB, Poole L, Allred R, Constant J, Pennington J, Porter S: Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 1998; 351:929-33
34. Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RM, Benjamin E: Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996; 334:1697-702
35. Abraham E, Glauser MP, Butler T, Garbino J, Gelmont D, Laterre PF, Kudsk K, Bruining HA, Otto C, Tobin E, Zwingelstein C, Lesslauer W, Leighton A: p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock: A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA 1997; 277:1531-8
36. Abraham E, Laterre PF, Garbino J, Pingleton S, Butler T, Dugernier T, Margolis B, Kudsk K, Zimmerli W, Anderson P, Reynaert M, Lew D, Lesslauer W, Passe S, Cooper P, Burdeska A, Modi M, Leighton A, Salgo M, Van der Auwera P: Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit Care Med 2001; 29:503-10
37. Opal SM, Cohen J: Clinical gram-positive sepsis: Does it fundamentally differ from gram-negative bacterial sepsis? Crit Care Med 1999; 27:1608-16
38. Silverstein R, Norimatsu M, Morrison DC: Fundamental differences during gram-positive vs. gram-negative sepsis become apparent during bacterial challenge of n-galactosamine-treated mice. J Endotoxin Res 1997; 4:173-81
39. Matuschak GM, Munoz C, Epperly NA, Britton RS, Walsh D, Schilly DR, Tredway TL, Khan TA, Bacon BR, Lechner AJ: TNF-alpha and IL-6 expression in perfused rat liver after intraportal candidemia vs. E. coli or S. aureus bacteremia. Am J Physiol 1994; 267:R446-54
40. Cui W, Morrison DC, Silverstein R: Differential tumor necrosis factor alpha expression and release from peritoneal mouse macrophages in vitro in response to proliferating gram-positive versus gram-negative bacteria. Infect Immun 2000; 68:4422-9
41. Karzai W, von Specht BU, Parent C, Haberstroh J, Wollersen K, Natanson C, Banks SM, Eichacker PQ: G-CSF during Escherichia coli versus Staphylococcus aureus pneumonia in rats has fundamentally different and opposite effects. Am J Respir Crit Care Med 1999; 159:1377-82
42. Parent C, Eichacker PQ: Granulocyte colony stimulating factor as therapy for pneumonia and sepsis in the nonneutropenic host: Preclinical and clinical trials, Evolving Concepts in Sepsis and Septic Shock. Edited by Eichacker PQ. Norwell, MA, Kluwer Academic Publishers, 2001, pp 175-87
43. Espevik T, Nissen-Meyer J: A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods 1986; 95:99-105
44. Miller RG: Survival Analysis. New York, John Wiley and Sons, Inc., 1981
45. Snedcor GW, Cochran WG: Statistical Methods, Ames, Iowa State University Press, 1980
46. Gamble JR, Harlan JM, Klebanoff SJ, Vadas MA: Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc Natl Acad Sci U S A 1985; 82:8667-71
47. Pohlman TH, Stanness KA, Beatty PG, Ochs HD, Harlan JM: An endothelial cell surface factor(s) induced in vitro by lipopolysaccharide, interleukin 1, and tumor necrosis factor-alpha increases neutrophil adherence by a CDwl8-dependent mechanism. J Immunol 1986; 136:4548-53
48. Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, Hariri RJ, Fahey TJ III, Zentella A, Albert JD, Shires GT, Cerami A: Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234:470-4
49. Wang P, Wood TJ, Zhou M, Ba ZF, Chaudry IH: Inhibition of the biologic activity of tumor necrosis factor maintains vascular endothelial cell function during hyperdynamic sepsis. J Trauma 1996; 40:694-700; discussion 701-1
50. Meduri GU: The bi-directional effect of inflammation on bacterial growth: A new insight into the role of glucocorticoids in the resolution of severe infections, Evolving Concepts in Sepsis and Septic Shock. Edited by Eichacker PQ, Pugin J. Norwell, MA, Kluwer Academic Publishers, 2001, pp 111-27
51. Luo G, Niesel DW, Shaban RA, Grimm EA, Klimpel GR: Tumor necrosis factor alpha binding to bacteria: Evidence for a high-affinity receptor and alteration of bacterial virulence properties. Infect Immun 1993; 61:830-5
52. Meduri GU, Kanangat S, Stefan J, Tolley E, Schaberg D: Cytokines IL-1beta, IL-6, and TNF-alpha enhance in vitro growth of bacteria. Am J Respir Crit Care Med 1999; 160:961-7
53. Kanangat S, Meduri GU, Tolley EA, Patterson DR, Meduri CU, Pak C, Griffin JP, Bronze MS, Schaberg DR: Effects of cytokines and endotoxin on the intracellular growth of bacteria. Infect Immun 1999; 67:2834-40
54. Nelson S, Bagby GJ: Granulocyte colony stimulating factor and modulation of inflammatory cells in sepsis. Clin Chest Med 1996; 17:319-32
55. Eichacker PQ, Parent C, Kalil A, Esposito C, Cui X, Banks SM, Gerstenberger EP, Fitz Y, Danner RL, Natanson C: Risk and the efficacy of antiinflammatory agents: Retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 2002; 166:1197-205
56. Anti-infective Drugs Advisory Committee: Drotrecogin alfa (activated) [Recombinant Human Activated Protein C rhAPC], FDA, 2001
57. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
58. Piper RD, Cook DJ, Bone RC, Sibbald WJ: Introducing critical appraisal to studies of animal models investigating novel therapies in sepsis. Crit Care Med 1996; 24:2059-70
59. Tutor JD, Mason CM, Dobard E, Beckerman RC, Summer WR, Nelson S: Loss of compartmentalization of alveolar tumor necrosis factor after lung injury. Am J Respir Crit Care Med 1994; 149:1107-11
60. Nelson S, Bagby GJ, Bainton BG, Wilson LA, Thompson JJ, Summer WR: Compartmentalization of intraalveolar and systemic lipopolysaccharide-induced tumor necrosis factor and the pulmonary inflammatory response. J Infect Dis 1989; 159:189-94
61. Li XY, Donaldson K, Brown D, MacNee W: The role of tumor necrosis factor in increased airspace epithelial permeability in acute lung inflammation. Am J Respir Cell Mol Biol 1995; 13:185-95
62. Kurahashi K, Kajikawa O, Sawa T, Ohara M, Gropper MA, Frank DW, Martin TR, Wiener-Kronish JP: Pathogenesis of septic shock in Pseudomonas aeruginosa pneumonia. J Clin Invest 1999; 104:743-50